Implementation of precision cancer medicine requires structured reporting of clinical actionable molecular alterations. The growing number of targeted anticancer drugs in clinical use and development necessitates a hierarchical ontology that focuses on the interactions between drugs and their targets and the impact of drug classes. Here we report the development of NCT POT (National Center for Tumor Diseases Drug Precision Oncology Thesaurus) Drugs, a manually curated cancer drug class ontology that integrates multiple data sources. This easily accessible resource is part of the NCT POT framework and can be downloaded at https://github.com/TMO-HD/nct-thesaurus with detailed documentation.

S.K.: Consulting or advisory board membership: Roche; honoraria: Roche. P.H.: Consulting or advisory board membership: Platomics; honoraria: Platomics, Roche. S.F.: Consulting or advisory board membership: Bayer, Illumina, Roche; honoraria: Amgen, Eli Lilly, PharmaMar, Roche; research funding: AstraZeneca, Pfizer, PharmaMar, Roche; travel or accommodation expenses: Amgen, Eli Lilly, Illumina, PharmaMar, Roche.

This work was supported by the NCT Molecular Precision Oncology Program and the NCT Donations against Cancer Program.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Financial support: This work was supported by the NCT Molecular Precision Oncology Program and the NCT Donations against Cancer Program.

Authors’ disclosures: S.K.: Consulting or advisory board membership: Roche; honoraria: Roche. P.H.: Consulting or advisory board membership: Platomics; honoraria: Platomics, Roche. S.F.: Consulting or advisory board membership: Bayer, Illumina, Roche; honoraria: Amgen, Eli Lilly, PharmaMar, Roche; research funding: AstraZeneca, Pfizer, PharmaMar, Roche; travel or accommodation expenses: Amgen, Eli Lilly, Illumina, PharmaMar, Roche.